Interpretation on systemic therapy for advanced hepatocellular carcinoma:ASCO guideline update
ZHOU Rui
CHEN Ya-jin
Abstract：On March 19,2024,the American Society of Clinical Oncology(ASCO)released an update to the guidelines for the systemic treatment of advanced hepatocellular carcinoma(HCC).This update,based on eight phase Ⅲrandomized controlled trials(RCTs)from the 2020 ASCO guidelines,integrated ten latest RCT data in recent years and recommended atezolizumab plus bevacizumab or durvalumab plus tremelimumab as the preferred first-line treatment for advanced HCC patients with Child-Pugh A status and ECOG PS 0-1.It also addressed the selection of second-line and subsequent-line treatments for advanced HCC patients.
Keywords：advanced hepatocellular carcinomathe Ameri-can Society of Clinical Oncologysystemic therapy
Publication Date：2024-07-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 733-736 )